Can confirm — same results here.

Clinical perspective on ClinicalTrials.gov GLP-1 trial tracker :

I have managed over 200 patients on GLP-1 therapy and this topic comes up frequently. What the data shows — and what I see in practice — is that proper titration prevents most adverse events.

For this specific question, I would recommend: reviewing the relevant clinical guidelines.

Want to share my personal experience related to ClinicalTrials.gov GLP-1 trial since I think it might help others in a similar situation.

I started my GLP-1 journey in March 2025 at 286 lbs with metabolic syndrome. My telehealth provider prescribed semaglutide 0.25mg to start.

Now, 10 months later: I am down 76 lbs, my labs have normalized, and my sleep apnea has improved dramatically. The ClinicalTrials.gov aspect specifically was something that made a big difference in my journey.

This forum was my go-to resource throughout.

LindaRN_retired — that is really helpful context on ClinicalTrials.gov GLP-1. Follow-up question: did you change anything about your diet at the same time?

I am in a similar situation (month 2) and trying to set realistic expectations.

To answer EndoResFellow's question specifically:

From a clinical standpoint, ClinicalTrials.gov GLP-1 trial is well-supported by the literature.

The short answer: follow the standard titration protocol and reassess at 4-6 weeks.

The longer answer involves pharmacokinetic considerations around steady-state concentrations, which I am happy to elaborate on if helpful.